Eli Lilly and Company $LLY Shares Acquired by EP Wealth Advisors LLC

Key Points

• EP Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 103.7% in Q1, owning 69,144 shares valued at $57.1 million after acquiring an additional 35,207 shares.
• Analysts have mixed ratings on Eli Lilly, with Wall Street Zen upgrading the stock to a "strong-buy", while Deutsche Bank reduced its target price from $1,010 to $900.
• Eli Lilly announced a quarterly dividend of $1.50 per share, representing an annual yield of 0.8%, to be paid on September 10th.

EP Wealth Advisors LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 103.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 69,144 shares of the company's stock after buying an additional 35,207 shares during the period. EP Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $57,106,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of LLY. WestEnd Advisors LLC raised its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company in the 1st quarter worth about $27,000. Citizens National Bank Trust Department boosted its position in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter worth about $40,000. Finally, Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $43,000. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.1%

NYSE:LLY traded up $1.08 on Wednesday, hitting $736.27. 2,220,178 shares of the stock were exchanged, compared to its average volume of 4,151,698. The stock has a market capitalization of $696.85 billion, a price-to-earnings ratio of 48.12, a P/E/G ratio of 1.02 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $954.00. The company's 50-day moving average price is $747.03 and its 200 day moving average price is $783.75.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the firm posted $3.92 earnings per share. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio is currently 39.22%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. HSBC upgraded Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their price target for the company from $675.00 to $700.00 in a report on Wednesday, August 27th. Daiwa America lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Saturday. Leerink Partners reissued a "market perform" rating and issued a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $950.17.

Insider Transactions at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger bought 117 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.